Shares dropped sharply as Johnson & Johnson's Q3 report delivered a paradox: headline numbers that technically cleared the bar, but underlying details that spooked investors. Revenue rose 5.9% to $25.4 billion and adjusted EPS came in at $2.59 , while GAAP net earnings collapsed 96% to just $210 million — a chasm between "adjusted" and real profit that raises legitimate earnings-quality concerns. With the stock at $252.52, down 4.3%, the sell-off suggests Wall Street is pricing in more than one quarter of softness.
• The Profit Gap Is Hard to Ignore
Reported EPS was just $0.09, reflecting one-time charges for J&J's proposed talc litigation settlement, the Firefly Bio acquisition, and a collaboration deal with Sail Biomedicines . The adjusted earnings also exclude rising separation costs for the orthopedics spinoff — $746 million after tax in the first nine months, increasing each quarter . When the bridge between GAAP and adjusted earnings spans billions, investors rightfully ask how much "recurring" profit is real.
• Wars Abroad Are Cutting Into Device Sales at Home on the Balance Sheet
MedTech sales rose only 2.5% to $8.6 billion, missing estimates of $8.71 billion . CFO Joe Wolk said the Middle East conflict, European austerity, and China pricing pressures weighed on international results . Gulf states like Kuwait, UAE, and Saudi Arabia "pride themselves on having solid healthcare," Wolk said, but "their budgets now are being resourced and allocated towards defence."
Outside the U.S., MedTech division sales were essentially flat — a warning for a segment that accounts for roughly a third of total revenue.
• Tremfya Is Carrying the Weight — But One Drug Can't Do It All
Tremfya, J&J's immune-disease treatment, surged 68% to $2.4 billion, beating estimates of $2.19 billion , offsetting a 54% decline in Stelara as generics eat into that franchise. Meanwhile, blood-cancer drug Darzalex grew 16% to $4.24 billion but missed the Street's $4.4 billion target . Pharma strength is real but unevenly distributed.
• The Orthopedics Spinoff Adds Strategic Clarity — and Near-Term Cost
J&J confirmed it is targeting a mid-2027 spinoff of DePuy Synthes, its hip-and-knee implant unit, marking its second major corporate separation . Apollo Global Management is reportedly in talks to buy the unit for roughly $20 billion . A sale would bring immediate cash; a spinoff rewards patient shareholders but keeps separation costs climbing.
The guidance raise — full-year sales midpoint nudged to $101.2 billion, adjusted EPS midpoint lifted to $11.10 — was modest enough to feel like a floor, not a catalyst. J&J's pharmaceutical engine is humming, but until geopolitical headwinds ease and the earnings-quality gap narrows, today's selloff is the market demanding proof, not promises.